Targeting Pim Kinases and DAPK3 to Control Hypertension

David A. Carlson, Miriam R. Singer, Cindy Sutherland, Clara Redondo, Leila T. Alexander, Philip F. Hughes, Stefan Knapp, Susan Gurley, Matthew A. Sparks, Justin A. MacDonald, Timothy A.J. Haystead

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Sustained vascular smooth muscle hypercontractility promotes hypertension and cardiovascular disease. The etiology of hypercontractility is not completely understood. New therapeutic targets remain vitally important for drug discovery. Here we report that Pim kinases, in combination with DAPK3, regulate contractility and control hypertension. Using a co-crystal structure of lead molecule (HS38) in complex with DAPK3, a dual Pim/DAPK3 inhibitor (HS56) and selective DAPK3 inhibitors (HS94 and HS148) were developed to provide mechanistic insight into the polypharmacology of hypertension. In vitro and ex vivo studies indicated that Pim kinases directly phosphorylate smooth muscle targets and that Pim/DAPK3 inhibition, unlike selective DAPK3 inhibition, significantly reduces contractility. In vivo, HS56 decreased blood pressure in spontaneously hypertensive mice in a dose-dependent manner without affecting heart rate. These findings suggest including Pim kinase inhibition within a multi-target engagement strategy for hypertension management. HS56 represents a significant step in the development of molecularly targeted antihypertensive medications. Carlson et al. use crystal structure-guided medicinal chemistry techniques to develop a dual Pim/DAPK3 inhibitor (HS56) that reduces myosin phosphorylation and contractility in smooth muscle. Their findings reveal the contribution of Pim kinases to the pathology of hypertension, suggesting a novel multi-target engagement strategy for molecularly targeted antihypertensive medications.

Original languageEnglish (US)
Pages (from-to)1195-1207.e32
JournalCell Chemical Biology
Volume25
Issue number10
DOIs
StatePublished - Oct 18 2018
Externally publishedYes

Fingerprint

Hypertension
Muscle
Antihypertensive Agents
Crystal structure
Smooth Muscle
Polypharmacology
Phosphorylation
Blood pressure
Pathology
Myosins
Pharmaceutical Chemistry
Drug Discovery
Vascular Smooth Muscle
Cardiovascular Diseases
Heart Rate
Molecules
proto-oncogene proteins pim
Blood Pressure
Therapeutics
Lead

Keywords

  • DAPK3
  • death associated protein kinase
  • hypertension
  • Pim kinase
  • Pim-1
  • Pim-2
  • Pim-3
  • vascular smooth muscle contractility
  • ZIPK
  • zipper-interacting protein kinase

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Carlson, D. A., Singer, M. R., Sutherland, C., Redondo, C., Alexander, L. T., Hughes, P. F., ... Haystead, T. A. J. (2018). Targeting Pim Kinases and DAPK3 to Control Hypertension. Cell Chemical Biology, 25(10), 1195-1207.e32. https://doi.org/10.1016/j.chembiol.2018.06.006

Targeting Pim Kinases and DAPK3 to Control Hypertension. / Carlson, David A.; Singer, Miriam R.; Sutherland, Cindy; Redondo, Clara; Alexander, Leila T.; Hughes, Philip F.; Knapp, Stefan; Gurley, Susan; Sparks, Matthew A.; MacDonald, Justin A.; Haystead, Timothy A.J.

In: Cell Chemical Biology, Vol. 25, No. 10, 18.10.2018, p. 1195-1207.e32.

Research output: Contribution to journalArticle

Carlson, DA, Singer, MR, Sutherland, C, Redondo, C, Alexander, LT, Hughes, PF, Knapp, S, Gurley, S, Sparks, MA, MacDonald, JA & Haystead, TAJ 2018, 'Targeting Pim Kinases and DAPK3 to Control Hypertension', Cell Chemical Biology, vol. 25, no. 10, pp. 1195-1207.e32. https://doi.org/10.1016/j.chembiol.2018.06.006
Carlson DA, Singer MR, Sutherland C, Redondo C, Alexander LT, Hughes PF et al. Targeting Pim Kinases and DAPK3 to Control Hypertension. Cell Chemical Biology. 2018 Oct 18;25(10):1195-1207.e32. https://doi.org/10.1016/j.chembiol.2018.06.006
Carlson, David A. ; Singer, Miriam R. ; Sutherland, Cindy ; Redondo, Clara ; Alexander, Leila T. ; Hughes, Philip F. ; Knapp, Stefan ; Gurley, Susan ; Sparks, Matthew A. ; MacDonald, Justin A. ; Haystead, Timothy A.J. / Targeting Pim Kinases and DAPK3 to Control Hypertension. In: Cell Chemical Biology. 2018 ; Vol. 25, No. 10. pp. 1195-1207.e32.
@article{e403d87ae66a4a9d9d9aa82d265774bd,
title = "Targeting Pim Kinases and DAPK3 to Control Hypertension",
abstract = "Sustained vascular smooth muscle hypercontractility promotes hypertension and cardiovascular disease. The etiology of hypercontractility is not completely understood. New therapeutic targets remain vitally important for drug discovery. Here we report that Pim kinases, in combination with DAPK3, regulate contractility and control hypertension. Using a co-crystal structure of lead molecule (HS38) in complex with DAPK3, a dual Pim/DAPK3 inhibitor (HS56) and selective DAPK3 inhibitors (HS94 and HS148) were developed to provide mechanistic insight into the polypharmacology of hypertension. In vitro and ex vivo studies indicated that Pim kinases directly phosphorylate smooth muscle targets and that Pim/DAPK3 inhibition, unlike selective DAPK3 inhibition, significantly reduces contractility. In vivo, HS56 decreased blood pressure in spontaneously hypertensive mice in a dose-dependent manner without affecting heart rate. These findings suggest including Pim kinase inhibition within a multi-target engagement strategy for hypertension management. HS56 represents a significant step in the development of molecularly targeted antihypertensive medications. Carlson et al. use crystal structure-guided medicinal chemistry techniques to develop a dual Pim/DAPK3 inhibitor (HS56) that reduces myosin phosphorylation and contractility in smooth muscle. Their findings reveal the contribution of Pim kinases to the pathology of hypertension, suggesting a novel multi-target engagement strategy for molecularly targeted antihypertensive medications.",
keywords = "DAPK3, death associated protein kinase, hypertension, Pim kinase, Pim-1, Pim-2, Pim-3, vascular smooth muscle contractility, ZIPK, zipper-interacting protein kinase",
author = "Carlson, {David A.} and Singer, {Miriam R.} and Cindy Sutherland and Clara Redondo and Alexander, {Leila T.} and Hughes, {Philip F.} and Stefan Knapp and Susan Gurley and Sparks, {Matthew A.} and MacDonald, {Justin A.} and Haystead, {Timothy A.J.}",
year = "2018",
month = "10",
day = "18",
doi = "10.1016/j.chembiol.2018.06.006",
language = "English (US)",
volume = "25",
pages = "1195--1207.e32",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Targeting Pim Kinases and DAPK3 to Control Hypertension

AU - Carlson, David A.

AU - Singer, Miriam R.

AU - Sutherland, Cindy

AU - Redondo, Clara

AU - Alexander, Leila T.

AU - Hughes, Philip F.

AU - Knapp, Stefan

AU - Gurley, Susan

AU - Sparks, Matthew A.

AU - MacDonald, Justin A.

AU - Haystead, Timothy A.J.

PY - 2018/10/18

Y1 - 2018/10/18

N2 - Sustained vascular smooth muscle hypercontractility promotes hypertension and cardiovascular disease. The etiology of hypercontractility is not completely understood. New therapeutic targets remain vitally important for drug discovery. Here we report that Pim kinases, in combination with DAPK3, regulate contractility and control hypertension. Using a co-crystal structure of lead molecule (HS38) in complex with DAPK3, a dual Pim/DAPK3 inhibitor (HS56) and selective DAPK3 inhibitors (HS94 and HS148) were developed to provide mechanistic insight into the polypharmacology of hypertension. In vitro and ex vivo studies indicated that Pim kinases directly phosphorylate smooth muscle targets and that Pim/DAPK3 inhibition, unlike selective DAPK3 inhibition, significantly reduces contractility. In vivo, HS56 decreased blood pressure in spontaneously hypertensive mice in a dose-dependent manner without affecting heart rate. These findings suggest including Pim kinase inhibition within a multi-target engagement strategy for hypertension management. HS56 represents a significant step in the development of molecularly targeted antihypertensive medications. Carlson et al. use crystal structure-guided medicinal chemistry techniques to develop a dual Pim/DAPK3 inhibitor (HS56) that reduces myosin phosphorylation and contractility in smooth muscle. Their findings reveal the contribution of Pim kinases to the pathology of hypertension, suggesting a novel multi-target engagement strategy for molecularly targeted antihypertensive medications.

AB - Sustained vascular smooth muscle hypercontractility promotes hypertension and cardiovascular disease. The etiology of hypercontractility is not completely understood. New therapeutic targets remain vitally important for drug discovery. Here we report that Pim kinases, in combination with DAPK3, regulate contractility and control hypertension. Using a co-crystal structure of lead molecule (HS38) in complex with DAPK3, a dual Pim/DAPK3 inhibitor (HS56) and selective DAPK3 inhibitors (HS94 and HS148) were developed to provide mechanistic insight into the polypharmacology of hypertension. In vitro and ex vivo studies indicated that Pim kinases directly phosphorylate smooth muscle targets and that Pim/DAPK3 inhibition, unlike selective DAPK3 inhibition, significantly reduces contractility. In vivo, HS56 decreased blood pressure in spontaneously hypertensive mice in a dose-dependent manner without affecting heart rate. These findings suggest including Pim kinase inhibition within a multi-target engagement strategy for hypertension management. HS56 represents a significant step in the development of molecularly targeted antihypertensive medications. Carlson et al. use crystal structure-guided medicinal chemistry techniques to develop a dual Pim/DAPK3 inhibitor (HS56) that reduces myosin phosphorylation and contractility in smooth muscle. Their findings reveal the contribution of Pim kinases to the pathology of hypertension, suggesting a novel multi-target engagement strategy for molecularly targeted antihypertensive medications.

KW - DAPK3

KW - death associated protein kinase

KW - hypertension

KW - Pim kinase

KW - Pim-1

KW - Pim-2

KW - Pim-3

KW - vascular smooth muscle contractility

KW - ZIPK

KW - zipper-interacting protein kinase

UR - http://www.scopus.com/inward/record.url?scp=85049324010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049324010&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2018.06.006

DO - 10.1016/j.chembiol.2018.06.006

M3 - Article

C2 - 30033129

AN - SCOPUS:85049324010

VL - 25

SP - 1195-1207.e32

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 10

ER -